IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.
暂无分享,去创建一个
F. Agou | J. Tamburini | V. Baud | G. Bismuth | N. Ifrah | C. Lacombe | F. Verdier | P. Mayeux | D. Bouscary | Sophie Park | F. Dreyfus | L. Léotoing | N. Chapuis | V. Bardet | A. Green | L. Willems
[1] Marcos González,et al. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. , 2009, Leukemia research.
[2] Nianxiang Zhang,et al. Highly Phosphorylated FOXO3A Is An Adverse Prognostic Factor in Acute Myeloid Leukemia. , 2009 .
[3] J. Tamburini,et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.
[4] M. Hung,et al. A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer , 2009, Clinical Cancer Research.
[5] S. Fröhling,et al. Deregulation of signaling pathways in acute myeloid leukemia. , 2008, Seminars in oncology.
[6] K. Shokat,et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.
[7] T. Obsil,et al. Structure/function relationships underlying regulation of FOXO transcription factors , 2008, Oncogene.
[8] G. Mills,et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation , 2008, Nature Cell Biology.
[9] Philippe Broët,et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.
[10] G. Kroemer,et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia , 2007, Oncogene.
[11] C. Billottet,et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.
[12] E. Greer,et al. FOXO transcription factors at the interface between longevity and tumor suppression , 2005, Oncogene.
[13] E. Solary,et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .
[14] D. Tindall,et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] V. Imbert,et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells , 2005 .
[16] G. Courtois,et al. Inhibition of NF-κB Activation by Peptides Targeting NF-κB Essential Modulator (NEMO) Oligomerization* , 2004, Journal of Biological Chemistry.
[17] Steven M Kornblau,et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.
[18] G. Courtois,et al. The Trimerization Domain of Nemo Is Composed of the Interacting C-terminal CC2 and LZ Coiled-coil Subdomains* , 2004, Journal of Biological Chemistry.
[19] J. Griffin,et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins , 2004, Oncogene.
[20] S. Anderson,et al. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.
[21] Ryuji Kobayashi,et al. IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a , 2004, Cell.
[22] A. Khwaja,et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.
[23] M. Carroll,et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.
[24] J. Cheong,et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.
[25] Stephen Adam,et al. Phosphorylation of Serine 256 Suppresses Transactivation by FKHR (FOXO1) by Multiple Mechanisms , 2002, The Journal of Biological Chemistry.
[26] Geert J. P. L. Kops,et al. The Forkhead Transcription Factor FoxO Regulates Transcription of p27Kip1 and Bim in Response to IL-21 , 2002, The Journal of Immunology.
[27] Michael B. Yaffe,et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport , 2002, The Journal of cell biology.
[28] D. Howard,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.
[29] E. Estey,et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.
[30] F. Barr. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma , 2001, Oncogene.
[31] D. Hedley,et al. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. , 2001, Cytometry.
[32] P. Charneau,et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] J. Lammers,et al. Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27KIP1 , 2000, Molecular and Cellular Biology.
[34] J. Lammers,et al. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1 , 2000, Current Biology.
[35] R. Medema,et al. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.
[36] K. Kaestner,et al. Unified nomenclature for the winged helix/forkhead transcription factors. , 2000, Genes & development.
[37] T. Hunter,et al. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[38] M. Greenberg,et al. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.
[39] R. Berger,et al. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. , 1997, Blood.
[40] Yalin H. Wei,et al. Cloning and characterization of the t(X;II) breakpoint from a leukemic cell line identify a new member of the forkhead gene family , 1994, Genes, chromosomes & cancer.
[41] J. Tamburini,et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. , 2006, Haematologica.
[42] V. Imbert,et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. , 2005, Blood.
[43] E. Solary,et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.
[44] Ryuji Kobayashi,et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. , 2004, Cell.
[45] G. Courtois,et al. Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. , 2004, The Journal of biological chemistry.